PR Newswire Clinical TrialsOriginal article
Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body
Phase 2positiveCS-1103Positive
AI Analysis
Summary
Clear Scientific announced positive Phase 2 results for CS-1103, a small-molecule sequestrant that binds and inactivates fentanyl, meeting all trial endpoints. Phase 3 is planned for H1 2027.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Phase 2 trial met all endpoints
Importance:7/10
Sentiment:
0.80
Phase 2 ResultsPositive DataSmall-moleculeSequestrantFentanyl
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 1, 2026 3:09 PM